Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Chris Williams

Chris Williams is recorded as COO at Cytek Biosciences, Inc. (CTKB). Cytek Biosciences, Inc. reported in an 8-K filed September 12, 2024 that Chris Williams resigned as Chief Operating Officer, effective September 27, 2024. Cytek Biosciences, Inc. reported in an 8-K filed November 1, 2022 that Chris Williams was appointed Chief Operating Officer, effective October 31, 2022. The proxy statement of Cytek Biosciences, Inc. reports total compensation of $2,338,447 for Chris Williams in fiscal 2024, including a base salary of $323,878.

“On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the "Company"), effective as of September 27, 2024, to pursue another career opportunity.”
Cytek Biosciences, Inc. Form 8-K, filed September 12, 2024 · Read the filing
“On October 31, 2022, the Board of Directors (the "Board") of Cytek Biosciences, Inc. (the "Company") announced the appointment of Chris Williams as the Company's Chief Operating Officer, effective October 31, 2022.”
Cytek Biosciences, Inc. Form 8-K, filed November 1, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Cytek Biosciences, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Cytek Biosciences, Inc. (CTKB) $323,878 $2,338,447

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.